Physician

Rama Koteswararao Koya, MD

According to 2025 Medicare claims, Rama Koya, MD (NPI: 1407895832) practices hematology/oncology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75601-4756.

Koya's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 609 traditional Medicare patients, billed 102,703 HCPCS/CPT codes, and received $1,821,905 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,352 prescription claims across 317 beneficiaries totaling $5,510,850 in drug costs, led by Lenvima (Lenvatinib Mesylate). DME data shows 26 claims. Open Payments data shows 40 records totaling $1,844. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,174,280 and ending at $1,821,905. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,079,736 to $5,510,850. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,989 to $1,748.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$943K$1.9M2015 Medicare payment: $1,174,280 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,118,656 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,646,992 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $743,050 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $395,985 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $827,586 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,634,331 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,886,572 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,825,349 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,821,905 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015631104,832$1,174,280
201684778,842$1,118,656
2017988101,386$1,646,992
201866343,166$743,050
201957317,257$395,985
202052932,980$827,586
2021572112,669$1,634,331
2022623152,553$1,886,572
2023674101,512$1,825,349
2024609102,703$1,821,905

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$2.8M$5.5M2015 Drug cost: $1,079,736 (USD; Tot_Drug_Cst)2016 Drug cost: $1,488,552 (USD; Tot_Drug_Cst)2017 Drug cost: $2,119,537 (USD; Tot_Drug_Cst)2018 Drug cost: $2,512,190 (USD; Tot_Drug_Cst)2019 Drug cost: $3,188,539 (USD; Tot_Drug_Cst)2020 Drug cost: $2,895,178 (USD; Tot_Drug_Cst)2021 Drug cost: $3,959,140 (USD; Tot_Drug_Cst)2022 Drug cost: $4,272,537 (USD; Tot_Drug_Cst)2023 Drug cost: $3,617,458 (USD; Tot_Drug_Cst)2024 Drug cost: $5,510,850 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20152391,809$1,079,736
20162461,793$1,488,552
20172562,035$2,119,537
20182531,702$2,512,190
20192961,950$3,188,539
20202961,753$2,895,178
20213211,967$3,959,140
20223161,972$4,272,537
20233182,191$3,617,458
20243172,352$5,510,850

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$14K$27K2015 Medicare payment: $27,469 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $5,766 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $9,776 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $5,816 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $6,444 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $4,376 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $3,170 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $2,364 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $14,155 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $602 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R217$27,469
2016N/R108$5,766
2017N/R54$9,776
20181125$5,816
2019N/R55$6,444
2020N/R47$4,376
2021N/R65$3,170
2022N/R56$2,364
2023N/R53$14,155
2024N/R26$602

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more268618$88
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more260363$59
80053Blood test, comprehensive group of blood chemicals4141,485$10
36415Insertion of needle into vein for collection of blood sample4241,973$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count4081,701$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
LenvimaLenvatinib Mesylate23690$565,794
CalquenceAcalabrutinib Maleate461,380$542,716
ErleadaApalutamide341,020$487,916
RevlimidLenalidomide35952$486,987
LenalidomideLenalidomide29816$464,069

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J8521Capecitabine, oral, 500 mgNN/R12$357
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R14$245

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.40$1,844AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Rama Koteswararao Koya, MD?

Tedicare shows public-source Medicare data for Rama Koteswararao Koya, MD (NPI 1407895832), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rama Koteswararao Koya, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rama Koteswararao Koya, MD?

Rama Koteswararao Koya, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Rama Koteswararao Koya, MD have Open Payments data?

Rama Koteswararao Koya, MD has 40 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.